CD22 and neoplasm: According to the expression of these antigens by tumor cells before the start of immunotherapy, we suggest either the consequent gating of the B-cell compartment using CD22 and then iCD79a (if both antigens are expressed strongly), or the application of one single antigen if the second antigen is not totally expressed.